Performance of whole-blood interferon-gamma release assay in patients admitted to the emergency department with pulmonary infiltrates

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Lee, Yoon J ^a   Lee, Jaehee ^a   Kim, Yi Y ^a   Won, Dong I ^a   Cha, Seung I ^a   Park, Jae Y ^a   Jung, Tae H ^a   Kim, Chang H ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EMERGENCY WARD; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOSPITAL PATIENT; HUMAN; HYPOALBUMINEMIA; IMMUNOASSAY; LUNG INFILTRATE; LUNG TUBERCULOSIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; QUANTIFERON TEST; WHOLE BLOOD INTERFERON GAMMA RELEASE ASSAY; AGED; ANALYTICAL EQUIPMENT; BLOOD; DIAGNOSTIC PROCEDURE; EMERGENCY HEALTH SERVICE; EVALUATION; IMMUNOLOGY; INSTRUMENTATION; INTERFERON GAMMA RELEASE ASSAY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSTIC TECHNIQUES AND PROCEDURES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENTS; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; TUBERCULOSIS, PULMONARY;

EID: 79955015020     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-107     Document Type: Article

References (29)

1. Pai M, Riley LW, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004, 4(12):761-776. 10.1016/S1473-3099(04)01206-X, 15567126.
2. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006, 174(7):736-742. 10.1164/rccm.200509-1516PP, 16799073.
3. Ferrara G, Losi M, Fabbri LM, Migliori GB, Richeldi L, Casali L. Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. Arch Immunol Ther Exp (Warsz) 2009, 57(6):425-433.
4. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005, 54(RR-15):49-55.
5. Connell TG, Rangaka MX, Curtis N, Wilkinson RJ. QuantiFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection?. Expert Rev Mol Diagn 2006, 6(5):663-677. 10.1586/14737159.6.5.663, 17009902.
6. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D'Amico R, Marchegiano P, Rumpianesi F, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005, 172(5):631-635. 10.1164/rccm.200502-196OC, 15961696.
7. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006, 367(9519):1328-1334. 10.1016/S0140-6736(06)68579-6, 16631911.
8. Beffa P, Zellweger A, Janssens JP, Wrighton-Smith P, Zellweger JP. Indeterminate test results of T-SPOT. TB performed under routine field conditions. Eur Respir J 2008, 31(4):842-846. 10.1183/09031936.00117207, 18057053.
9. Haustein T, Ridout DA, Hartley JC, Thaker U, Shingadia D, Klein NJ, Novelli V, Dixon GL. The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J 2009, 28(8):669-673. 10.1097/INF.0b013e3181a16394, 19633512.
10. Kobashi Y, Sugiu T, Mouri K, Obase Y, Miyashita N, Oka M. Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice. Eur Respir J 2009, 33(4):812-815. 10.1183/09031936.00075008, 19129287.
11. World Health Organization. Tuberculosis. Accessed July 10, 2007., http://www.who.int./tb
12. Kang YA, Lee HW, Hwang SS, Um SW, Han SK, Shim YS, Yim JJ. Usefulness of whole-blood interferon-gamma assay and interferon-gamma enzyme-linked immunospot assay in the diagnosis of active pulmonary tuberculosis. Chest 2007, 132(3):959-965. 10.1378/chest.06-2805, 17505029.
13. Cellestis QuantiFERON-TB Gold In-Tube package insert. 2009, Cellestis., http://www.cellestis.com
14. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149(3):177-184. 2951987, 18593687.
15. Mazurek GH, Weis SE, Moonan PK, Daley CL, Bernardo J, Lardizabal AA, Reves RR, Toney SR, Daniels LJ, LoBue PA. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis 2007, 45(7):837-845. 10.1086/521107, 17806047.
16. Fujita A, Ajisawa A, Harada N, Higuchi K, Mori T. Performance of a Whole-Blood Interferon-Gamma Release Assay with Mycobacterium RD1-Specific Antigens among HIV-Infected Persons. Clin Dev Immunol 2011,
17. Miranda C, Yen-Lieberman B, Terpeluk P, Tomford JW, Gordon S. Reducing the rates of indeterminate results of the QuantiFERON-TB Gold In-Tube test during routine preemployment screening for latent tuberculosis infection among healthcare personnel. Infect Control Hosp Epidemiol 2009, 30(3):296-298. 10.1086/595732, 19199532.
18. Herrera V, Yeh E, Murphy K, Parsonnet J, Banaei N. Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold in-tube assay. J Clin Microbiol 2010, 48(8):2672-2676. 10.1128/JCM.00482-10, 2916573, 20519472.
19. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340(6):448-454. 10.1056/NEJM199902113400607, 9971870.
20. Barbara J. Blood cells. A practical guide. 2006, 237-238. Wiley-Blackwell, 3.
21. Calcagni E, Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann N Y Acad Sci 2006, 1069:62-76. 10.1196/annals.1351.006, 16855135.
22. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986, 232(4753):977-980. 10.1126/science.3754653, 3754653.
23. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993, 119(12):1198-1208.
24. Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, Self C, Sinigaglia F. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997, 100(6):1513-1519. 10.1172/JCI119674, 508332, 9294119.
25. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.
26. Sodhi A, Gong J, Silva C, Qian D, Barnes PF. Clinical correlates of interferon gamma production in patients with tuberculosis. Clin Infect Dis 1997, 25(3):617-620. 10.1086/513769, 9314449.
27. Goletti D, Butera O, Bizzoni F, Casetti R, Girardi E, Poccia F. Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. J Infect Dis 2006, 194(7):984-992. 10.1086/507427, 16960787.
28. Zea AH, Culotta KS, Ali J, Mason C, Park HJ, Zabaleta J, Garcia LF, Ochoa AC. Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis 2006, 194(10):1385-1393. 10.1086/508200, 17054067.
29. Qiu L, Huang D, Chen CY, Wang R, Shen L, Shen Y, Hunt R, Estep J, Haynes BF, Jacobs WR, et al. Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses. J Infect Dis 2008, 198(10):1514-1519. 10.1086/592448, 2884371, 18811584.